Navigation Links
Abbott Announces Positive Nine-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent

Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognized internationally for their safety and effectiveness in treating patients with vascular disease.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

CONTACT: media, Karin Bauer Aranaz, +1-650-868-2999, or financial, TinaVentura, +1-847-935-9390, both of Abbott

Web site: http://www.abbott.com/

Ticker Symbol: (NYSE:ABT)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
3. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
4. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
5. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
6. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
7. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/23/2014)... , July 23, 2014 Inovio ... successful results from its randomized, double-blind, placebo-controlled ... with biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) ... or 18. Treatment with VGX-3100, Inovio,s HPV16/18-specific ... to CIN1 or no disease, meeting the ...
(Date:7/23/2014)...  The management team at Columbia Laboratories, Inc. ... conference call on July 31, 2014, to discuss ... 30, 2014.  The call details are as follows:Date: ... EDTDial-in numbers: , Toll free: (877) 870-4263 (U.S.), ... archive): , www.columbialabs.com , under ,Investor, or ...
(Date:7/23/2014)... Global healthcare company GSK reports ... headwinds, increased price competition and supply disruptions to its ... points out that the company is very much in ... be confident about long-term prospects as well as the ... CFO Simon Dingemans adds that the company ...
Breaking Medicine Technology:Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 3Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 4Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 5Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2
... SPRING, Md., June 20, 2011 The U.S. Food ... help advance the development and approval of an artificial ... United States. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... condition in which the pancreas produces little or no ...
... (NYSE Amex: CUR ) announced that it has ... Phase Ia trial to test the safety of NSI-189 for ... drug in healthy volunteers for safety and tolerability. NSI-189 is ... new neuron growth in the hippocampus, an area of the ...
Cached Medicine Technology:FDA Issues Draft Guidance for Early Version of an Artificial Pancreas System 2FDA Issues Draft Guidance for Early Version of an Artificial Pancreas System 3Neuralstem Updates NSI-189 Major Depression Trial 2Neuralstem Updates NSI-189 Major Depression Trial 3
(Date:7/23/2014)... on human cancer genes have been focused on the ... be translated in the form of amino acids thus ... regulatory region or activator which controls the expression and ... was known of the role exerted such DNA fragment ... in Nature in collaboration with the group ...
(Date:7/23/2014)... Irvine, Calif., July 23, 2014 A therapy combining ... of a gene inhibitor into the brain restored voluntary ... UC Irvine,s Reeve-Irvine Research Center have found. , In ... achieved this breakthrough by turning back the developmental clock ... corticospinal tract nerve connections and providing a scaffold so ...
(Date:7/23/2014)... This report defines and segments the ... the Middle East & Africa, and Americas) - Global ... with analysis and forecasts of the global revenue. The ... over $10 billion in 2014 to nearly $14 billion ... , browse 49 Market Tables and 10 Figures Spread ...
(Date:7/23/2014)... A Forever Recovery, an open-ended drug and ... great start and gives them a solid foundation in ... Internet Addiction section of its website at http://aforeverrecovery.com/behavioral-addictions/internet-addiction/ ... Internet addiction is not just as legitimate a disorder ... trapping more and more victims each year – particularly ...
(Date:7/23/2014)... Children and teens who lose a parent might face an ... study suggests. People who were children or teens when ... death during the study period than those who had not ... Although the study found an association between a parent,s ... wasn,t designed to prove cause-and-effect. Also, the increased risk ...
Breaking Medicine News(10 mins):Health News:Gene inhibitor, salmon fibrin restore function lost in spinal cord injury 2Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 2Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 3Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 4Health News:Latest A Forever Recovery Launches Internet Addiction Section on Website 2Health News:Parent's Death May Raise Risk of Early Death for Grown Children, Study Suggests 2
... significantly slow or halt science's ability to establish ... by industry, a team of scientists and lawyers ... caution that litigation's effects could seriously impair efforts ... variety of diseases, including Parkinson's disease, Alzheimer's disease ...
... blood flow to the brain, helps the bodies detoxify ... Alzheimer's, say researchers. ,"Exercise improves thinking and mental ... associate professor of medicine at the New York University ... Health Central. ,"Studies have shown that it works ...
... and PRK eye procedures are safe and effective, according ... recent American Academy of Ophthalmology’s //Joint Meeting. ,Researchers ... PRK treatments say both procedures provide stable, long term ... answer to those who doubt LASIK’s reliability, showing that ...
... big, juicy steak for dinner last night, adding a large amount ... For one in ten of us, that could be a big ... our diet, our bodies use it for energy. But patients with ... of Americans – are more likely to develop arthrosclerosis, or build-up ...
... the age when reading a newspaper means holding ... glasses, wavefront-optimized //lens technology may offer a better ... American Academy of Ophthalmology’s 2006 Joint Meeting. ... lenses developed using wavefront technology offer significant improvements ...
... Blaming the resurfacing of polio cases in the Indian ... //Delhi Chief Minister Sheila Dikshit Saturday said that around ... part of the Pulse Polio programme. ,"Delhi was ... occurrence of fresh cases, mostly due to migration of ...
Cached Medicine News:Health News:Fast-Multiplying Lawsuits Can Stymie Medical Science, Authors Warn 2Health News:Fast-Multiplying Lawsuits Can Stymie Medical Science, Authors Warn 3Health News:PRK and LASIK Surgeries ‘Safe and Effective 2Health News:Sugars in Liver Found to Clear Fats from the Bloodstream 2Health News:Beyond Bifocals: Wavefront Technology Benefits Patients With Presbyopia 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: